MDNAF (Medicenna Therapeutics) Cash per Share: $0.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDNAF Medicenna Therapeutics Corp MDNAF
29 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Cash per Share?

Medicenna Therapeutics MDNAF +9.74% 29 Cash per Share is $0.05 as of Jun. 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Medicenna Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 was $0.05.


Medicenna Therapeutics  (OTCPK:MDNAF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Medicenna Therapeutics Cash per Share Related Terms


Medicenna Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Cash per Share Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.35 0.18 0.22 0.06

Medicenna Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.14 0.09 0.06 0.05
MDNAF
29GF Score
Medicenna Therapeutics Corp MDNAF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Medicenna Therapeutics's Cash per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Medicenna Therapeutics's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.05 mean?
Medicenna Therapeutics (MDNAF) has a Cash per Share of $0.05 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Cash per Share too high?
Medicenna Therapeutics' current Cash per Share is $0.05. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Cash per Share compare to VRTX and REGN?
Medicenna Therapeutics' Cash per Share of $0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Cash per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Cash per Share of $0.05. The current Cash per Share is $0.05. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Cash per Share is $0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score

Get the complete analysis for MDNAF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price